Dual BCL-2/BCL-xL inhibitors (ABT-737 or ABT-263/Navitoclax) or selective inhibitor of BCL-xL (WEHI-539) are also available and some have already been shown to potentiate the effects of chemotherapy in breast cancers in preclinical studies13–15. The gene discussed is BCL2L1; the disease is breast carcinoma.